RE: Still12 Apr 2021 23:44
Hi Starres,
Great Post, I see what you mean about their excitement in Our POC:
John Glencross is chief executive of Calculus Capital, a company which specialises in investing in early-stage companies. He is particularly excited by two British companies: vaccine developer Scancell and Manchester-based Genedrive.
Scancell has recently received an investment of more than £40million from US investor Red Mile, an early investor in vaccine star BioNtech. Glencross says: 'Its vaccine targets the ability of the Covid virus's spike to bind to cells and a second 'N' protein which induces a strong T-cell response. So it may give greater protection against new variants.'
Genedrive, he says, has designed a PCR point-of-care Covid test to detect a positive patient in about 15 minutes with detection limits meeting the sensitivity requirements of the UK's Medicines and Healthcare products Regulatory Agency.